GM-CSF-based cancer vaccines

被引:253
作者
Dranoff, G
机构
[1] Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA
[2] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA
[3] Harvard Univ, Sch Med, Boston, MA USA
关键词
D O I
10.1034/j.1600-065X.2002.18813.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The crafting of genetic and biochemical techniques to identify cancer antigens yielded the unexpected discovery that immune recognition of tumors regularly accompanies cancer development. The failure of the host to suppress tumor formation or attenuate disease progression may thus reflect the limited immunogenicity of nascent tumors. One critical determinant of host immunity is the mixture of cytokines produced in the tumor microenvironment. We have compared a large number of secreted and surface molecules for their relative abilities to augment tumor immunity following gene transfer into cancer cells. In multiple murine models, granulocyte-macrophage colony stimulating factor (GM-CSF) proved to be the most potent immunostimulatory product. Vaccination with irradiated tumor cells engineered to secrete GMCSF involves enhanced tumor antigen presentation by recruited dendritic cells (DCs) and macrophages; the coordinated functions of CD4(+) and CD8(+) T cells, CD1d-restricted NKT cells and antibodies mediate protective immunity. The evaluation of this vaccination strategy in patients with advanced melanoma revealed the consistent induction of cellular and humoral antitumor responses capable of effectuating substantial necrosis of distant metastases. The formulation of simplified methods for manufacturing autologous, GM-CSF-secreting tumor cells has enabled more extensive clinical testing in diverse patient settings.
引用
收藏
页码:147 / 154
页数:8
相关论文
共 76 条
[1]   ANTITUMOR EFFECT INDUCED BY GRANULOCYTE/MACROPHAGE-COLONY-STIMULATING FACTOR GENE-MODIFIED TUMOR VACCINATION - COMPARISON OF ADENOVIRUS-MEDIATED AND RETROVIRUS-MEDIATED GENETIC TRANSDUCTION [J].
ABE, J ;
WAKIMOTO, H ;
YOSHIDA, Y ;
AOYAGI, M ;
HIRAKAWA, K ;
HAMADA, H .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1995, 121 (9-10) :587-592
[2]  
Armstrong CA, 1996, CANCER RES, V56, P2191
[3]   Immunobiology of dendritic cells [J].
Banchereau, J ;
Briere, F ;
Caux, C ;
Davoust, J ;
Lebecque, S ;
Liu, YT ;
Pulendran, B ;
Palucka, K .
ANNUAL REVIEW OF IMMUNOLOGY, 2000, 18 :767-+
[4]   Dendritic cells and the control of immunity [J].
Banchereau, J ;
Steinman, RM .
NATURE, 1998, 392 (6673) :245-252
[5]   Activation of NK Cells and T Cells by NKG2D, a Receptor for Stress-Inducible MICA [J].
Bauer, Stefan ;
Groh, Veronika ;
Wu, Jun ;
Steinle, Alexander ;
Phillips, Joseph H. ;
Lanier, Lewis L. ;
Spies, Thomas .
JOURNAL OF IMMUNOLOGY, 2018, 200 (07) :2231-2233
[6]  
Bausero M, 1995, CANCER GENE THER, V2, P309
[7]  
BERKNER KL, 1988, BIOTECHNIQUES, V6, P616
[8]   Human tumor antigens recognized by T lymphocytes [J].
Boon, T ;
vanderBruggen, P .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (03) :725-729
[9]   A universal granulocyte-macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines [J].
Borrello, I ;
Sotomayor, EM ;
Cooke, S ;
Levitsky, HI .
HUMAN GENE THERAPY, 1999, 10 (12) :1983-1991
[10]   MODEL PREDICTING SURVIVAL IN STAGE-I MELANOMA BASED ON TUMOR PROGRESSION [J].
CLARK, WH ;
ELDER, DE ;
GUERRY, D ;
BRAITMAN, LE ;
TROCK, BJ ;
SCHULTZ, D ;
SYNNESTVEDT, M ;
HALPERN, AC .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1989, 81 (24) :1893-1904